Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.

You may also be interested in...



Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch

Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.

Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch

Firm pays $150 million for the topical acne treatment; QLT continues sale of assets.

QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne

Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS066117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By